BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib

類似資料

• Ceritinib enhances the efficacy of trametinib in BRAF/NRAS-wild type melanoma cell lines
  著者:: Verduzco, Daniel, 等
  出版事項: (2017)
• Reading between the lines; understanding drug response in the post genomic era
  著者:: Alifrangis, Constantine C., 等
  出版事項: (2014)
• Exploiting genetic complexity in cancer to improve therapeutic strategies
  著者:: Garnett, Mathew J., 等
  出版事項: (2012)
• The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug response()
  著者:: Garnett, Mathew J, 等
  出版事項: (2014)
• BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
  著者:: Perna, Daniele, 等
  出版事項: (2015)